Allogeneic EBV-transformed B-lymphoblastoid Cell Line Lysate-pulsed Autologous Dendritic Cell Vaccine KSD-101

**Semantic type:** Cell|Immunologic Factor|Pharmacologic Substance

**Definition:** A cell-based cancer vaccine composed of autologous monocyte-derived dendritic cells (DCs) pulsed with allogeneic Epstein-Barr virus (EBV)-transformed B-lymphoblastoid cell line (BLCL) lysate, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, DCs are loaded with allogeneic EBV-transformed BLCL lysate. Upon re-administration of the allogeneic EBV-transformed BLCL lysate-pulsed autologous DC vaccine KSD-101, the immune system is exposed to EBV-specific antigens, which stimulates the induction of a specific cytotoxic T-lymphocyte (CTL) response against EBV-positive tumor cells or EBV-infected cells. This results in cell lysis and inhibition of cancer cell proliferation. EBV, a ubiquitous human herpes virus, is associated with various malignancies.

**Synonyms:** - Allogeneic EBV-transformed BLCL Lysate-pulsed Autologous DC Vaccine KSD-101 - KSD 101 - KSD-101 - KSD101